Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 15 of 15
Date Sort ascending
CL_2024-15.pdf

INFORMATION ONLY
Takeda Product Updates

Customer Letter 2024-15 (PDF) | Takeda Letter (PDF)

CL_2024-14.pdf

INFORMATION ONLY
Release of Revised Circulars of Information for Pooled Platelets Psoralen Treated, Apheresis Platelets Psoralen Treated and Apheresis Platelets PAS Added

Customer Letter 2024-14 (PDF)

CL_2024-13.pdf

INFORMATION ONLY
Further updates to Ig Transitions FAQ regarding the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP)

Customer Letter 2024-13 (PDF) | 2024 Ig Transition FAQ (PDF)

CL_2024-12.pdf

INFORMATION ONLY
Hizentra 20% 10g Pre-Filled Syringe Update

Customer Letter 2024-12 (PDF) | Hizentra® 50mL Pre-filled Syringe (PDF)Hizentra® Tool (PDF)

CL_2024-11.pdf

INFORMATION ONLY
Glassia Update

Customer Letter 2024-11 (PDF) | Glassia Implementation FAQ (PDF)

CL_2024-10.pdf

ACTION REQUIRED
National Deployment of Pathogen-Reduced Platelets: Sixth Update 

Customer Letter 2024-10 (PDF)

CL_2024-09.pdf

INFORMATION ONLY
Introducing Hizentra 20% 10g Pre-Filled Syringe

Customer Letter 2024-09 (PDF)

CL_2024-08.pdf

INFORMATION ONLY
Temporary Changes to Gammagard S/D

Customer Letter 2024-08 (PDF) | GAMMAGARD® Customer Letter (PDF)

CL_2024-07.pdf

INFORMATION ONLY
Updated FAQ for the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP)

Customer Letter 2024-07 (PDF) | 2024 Ig Transition FAQ (PDF)

CL_2024-06.pdf

INFORMATION ONLY
Updated NAC Recommendations for Use of Irradiated Blood Components in Canada

Customer Letter 2024-06 (PDF)

CL_2024-05.pdf

ACTION REQUIRED
New Visual Inspection Tool (VIT)

Customer Letter 2024-05 (PDF)

CL_2024-04.pdf

INFORMATION ONLY
Glassia Launch Update

Customer Letter 2024-04 (PDF) | Introducing GLASSIA® in Canada (PDF)

CL_2024-03.pdf

INFORMATION ONLY
Introducing Rebinyn 3000IU and Esperoct 3000IU

Customer Letter 2024-03 (PDF)

CL_2024-02.pdf

INFORMATION ONLY
Illegible Lots on CSL’s Alburex 25% 100mL

Customer Letter 2024-02 (PDF) | Variable Printed Information on Alburex-25 Cartons (PDF)

CL_2024-01.pdf

INFORMATION ONLY
Discontinuation of Directed Donations

Customer Letter 2024-01 (PDF)